Xenograft News and Research

RSS

Xenograft are the cells of one species transplanted to another species.

$Breakthrough alpha-ray treatment of iodine-refractory thyroid cancer with multiple metastases$

Breakthrough alpha-ray treatment of iodine-refractory thyroid cancer with multiple metastases

For many years, radioactive iodine which emits beta rays has been used for treatment of thyroid cancer. Generally, 5-year survival rates may exceed 90%.

2 Apr 2019

Researchers identify marker protein that offers both diagnostic and therapeutic function

Of all gastrointestinal cancers, pancreatic cancer is one of the most aggressive. Because of this, it has a very low 5-year survival rate of just 5% and a median survival time below 6 months. Additionally, treatment is difficult, with only surgery shown to provide a cure. However, the vast majority of patients have tumors that cannot be removed surgically or their cancer is too advanced or spread too far to be treatable.

24 Jan 2019

Researchers identify multiple new subtypes of most common childhood cancer

Like cartographers completing a map, investigators have identified multiple new subtypes of the most common childhood cancer--research that will likely improve the diagnosis and treatment of high-risk patients.

14 Jan 2019

St. Jude Hospital announces availability of largest collections of leukemia samples

St. Jude Children's Research Hospital today announced the availability of one of the world's largest collections of leukemia samples from children and adults.

15 Nov 2018

Study identifies potential therapeutic strategy for patients with clear cell renal cancer

Researchers have provided new insight on the mechanisms behind the development of clear cell Renal Cell Carcinoma (ccRCC), according to new findings published in eLife.

13 Nov 2018

New nuclear medicine tracer could improve diagnosis, treatment of non-small cell lung cancer

Researchers have developed a new nuclear medicine tracer that could improve diagnosis and treatment of non-small cell lung cancer.

7 Nov 2018

Crown Bioscience announces successful validation of well-characterized prostate cancer PDX models

Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, has announced the addition of unique, well characterized, fully annotated patient-derived xenograft models of prostate cancer.

27 Sep 2018

Hybrid theranostic complex shows high therapeutic efficacy against tumor cells

Emerging cancer nanotechnology enables target-delivery of substantial payloads of drugs to cancer sites with concomitant reduction of side-effects due to the lesser accumulation in the critical organs.

25 Sep 2018

Modified natural killer cells may be new player in CAR-T immunotherapies

Emerging CAR-T immunotherapies leverage modified versions of patient's T-cells to target and kill cancer cells.

29 Jun 2018

AntiCancer's oral drug overcomes gemcitabine resistance in mouse models of human pancreatic cancer

Pancreatic cancer is lethal in about 95% of cases mostly due to failure of first-line therapy gemcitabine. AntiCancer Inc.'s oral methioninase (AC 00619), which is in late pre-clinical development as an anti-cancer as well as an anti-aging drug, has now been shown to overcome gemcitabine resistance in mouse models of human pancreatic cancer, including AntiCancer's patient-derived orthotopic xenograft mouse models.

25 Jun 2018

Unusual cell-to-cell communication in glioblastoma promotes aggressiveness and therapy resistance

A surprising form of cell-to-cell communication in glioblastoma promotes global changes in recipient cells, including aggressiveness, motility, and resistance to radiation or chemotherapy.

22 Jun 2018

Scientists develop novel computational framework to support personalized cancer treatment

Researchers at Columbia University Irving Medical Center have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug combinations that are most likely to kill them.

19 Jun 2018

Salk researchers develop new glioblastoma model using gene-edited organoids

Glioblastoma multiforme (GBM) is an incredibly deadly brain cancer and presents a serious black box challenge. It's virtually impossible to observe how these tumors operate in their natural environment and animal models don't always provide good answers.

25 Apr 2018

Role of extrachromosomal pieces of DNA in cancer development and treatment resistance

Glioblastoma is the most common and aggressive form of brain cancer. Response to standard-of-care treatment is poor, with a two-year survival rate of only 15 percent.

24 Apr 2018

Researchers develop highly specific apoptosis assay for pharmacodynamic analyses of tumor specimens

Existing microscopy-based methods of detecting apoptosis, such as TUNEL (terminal deoxynucleotidyl transferase dUTP nick-end labeling), have limited quantitative capabilities due to insufficient signal-to-noise ratios.

19 Apr 2018

UCSF researchers find new way to attack common drivers of 'undruggable' cancers

Cancer researchers have made great strides in developing targeted therapies that treat the specific genetic mutations underlying a patient's cancer.

24 Jan 2018

Enzyme inhibitor and chemotherapy combination regresses glioblastoma

In animal experiments, a human-derived glioblastoma significantly regressed when treated with the combination of an experimental enzyme inhibitor and the standard glioblastoma chemotherapy drug, temozolomide.

24 Jan 2018

Prostate cancer’s gene-determined ‘immune landscape’ dictates tumor progression

The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of patients, suggesting that as-yet unidentified variations among tumors result in distinct paths of disease progression and response to therapy.

12 Jan 2018

Researchers identify novel mechanism that protects from brain tumor

A group of researchers at the Spanish National Cancer Research Centre have identified a protein called RanBP6 as a new regulator of EGFR. In a paper published in Nature Communications they show how silencing of RanBP6 promoted glioma growth, by upregulating EGFR expression.

18 Dec 2017

Study provides new insights into mechanism of tumor survival in glioblastoma

A Northwestern Medicine study, published in the journal Cancer Cell, has provided new insights into a mechanism of tumor survival in glioblastoma and demonstrated that inhibiting the process could enhance the effects of radiation therapy.

11 Dec 2017